199 related articles for article (PubMed ID: 17014917)
21. Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex.
Ohtake N; Saito M; Eto M; Seki K
Regul Pept; 2014 May; 190-191():1-11. PubMed ID: 24769307
[TBL] [Abstract][Full Text] [Related]
22. Regulation of α-secretase ADAM10 expression and activity.
Endres K; Fahrenholz F
Exp Brain Res; 2012 Apr; 217(3-4):343-52. PubMed ID: 21969210
[TBL] [Abstract][Full Text] [Related]
23. Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis.
Kojro E; Füger P; Prinzen C; Kanarek AM; Rat D; Endres K; Fahrenholz F; Postina R
J Alzheimers Dis; 2010; 20(4):1215-31. PubMed ID: 20413873
[TBL] [Abstract][Full Text] [Related]
24. Extract of Caragana sinica as a potential therapeutic option for increasing alpha-secretase gene expression.
Schuck F; Schmitt U; Reinhardt S; Freese C; Lee IS; Thines E; Efferth T; Endres K
Phytomedicine; 2015 Oct; 22(11):1027-36. PubMed ID: 26407945
[TBL] [Abstract][Full Text] [Related]
25. Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.
Reinhardt S; Stoye N; Luderer M; Kiefer F; Schmitt U; Lieb K; Endres K
Sci Rep; 2018 Jan; 8(1):1329. PubMed ID: 29358714
[TBL] [Abstract][Full Text] [Related]
26. Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region.
Lammich S; Buell D; Zilow S; Ludwig AK; Nuscher B; Lichtenthaler SF; Prinzen C; Fahrenholz F; Haass C
J Biol Chem; 2010 May; 285(21):15753-60. PubMed ID: 20348102
[TBL] [Abstract][Full Text] [Related]
27. Alpha-secretase as a therapeutic target.
Fahrenholz F
Curr Alzheimer Res; 2007 Sep; 4(4):412-7. PubMed ID: 17908044
[TBL] [Abstract][Full Text] [Related]
28. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10.
Donmez G; Wang D; Cohen DE; Guarente L
Cell; 2010 Jul; 142(2):320-32. PubMed ID: 20655472
[TBL] [Abstract][Full Text] [Related]
29. Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein.
Harris B; Pereira I; Parkin E
Brain Res; 2009 Nov; 1296():203-15. PubMed ID: 19679113
[TBL] [Abstract][Full Text] [Related]
30. Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice.
Ratia M; Giménez-Llort L; Camps P; Muñoz-Torrero D; Clos MV; Badia A
Pharmacol Biochem Behav; 2010 Jun; 95(4):485-93. PubMed ID: 20363245
[TBL] [Abstract][Full Text] [Related]
31. Effects of environmental enrichment on exploration, anxiety, and memory in female TgCRND8 Alzheimer mice.
Görtz N; Lewejohann L; Tomm M; Ambrée O; Keyvani K; Paulus W; Sachser N
Behav Brain Res; 2008 Aug; 191(1):43-8. PubMed ID: 18433890
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10).
Cheng C; Li W; Zhang Z; Yoshimura S; Hao Q; Zhang C; Wang Z
J Biol Chem; 2013 May; 288(19):13748-61. PubMed ID: 23546882
[TBL] [Abstract][Full Text] [Related]
33. Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels.
Marshall AJ; Rattray M; Vaughan PF
Brain Res; 2006 Jul; 1099(1):18-24. PubMed ID: 16762326
[TBL] [Abstract][Full Text] [Related]
34. Pen-2 overexpression induces Aβ-42 production, memory defect, motor activity enhancement and feeding behavior dysfunction in NSE/Pen-2 transgenic mice.
Nam SH; Seo SJ; Goo JS; Kim JE; Choi SI; Lee HR; Hwang IS; Jee SW; Lee SH; Bae CJ; Park JY; Kim HS; Shim SB; Hwang DY
Int J Mol Med; 2011 Dec; 28(6):961-71. PubMed ID: 21822534
[TBL] [Abstract][Full Text] [Related]
35. ADAM-10 over-expression increases cortical synaptogenesis.
Bell KF; Zheng L; Fahrenholz F; Cuello AC
Neurobiol Aging; 2008 Apr; 29(4):554-65. PubMed ID: 17187903
[TBL] [Abstract][Full Text] [Related]
36. Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo.
Endres K; Mitteregger G; Kojro E; Kretzschmar H; Fahrenholz F
Neurobiol Dis; 2009 Nov; 36(2):233-41. PubMed ID: 19632330
[TBL] [Abstract][Full Text] [Related]
37. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model.
Postina R; Schroeder A; Dewachter I; Bohl J; Schmitt U; Kojro E; Prinzen C; Endres K; Hiemke C; Blessing M; Flamez P; Dequenne A; Godaux E; van Leuven F; Fahrenholz F
J Clin Invest; 2004 May; 113(10):1456-64. PubMed ID: 15146243
[TBL] [Abstract][Full Text] [Related]
38. ADAM10 in synaptic physiology and pathology.
Musardo S; Marcello E; Gardoni F; Di Luca M
Neurodegener Dis; 2014; 13(2-3):72-4. PubMed ID: 24008925
[TBL] [Abstract][Full Text] [Related]
39. Sox2 functionally interacts with βAPP, the βAPP intracellular domain and ADAM10 at a transcriptional level in human cells.
Sarlak G; Htoo HH; Hernandez JF; Iizasa H; Checler F; Konietzko U; Song W; Vincent B
Neuroscience; 2016 Jan; 312():153-64. PubMed ID: 26592717
[TBL] [Abstract][Full Text] [Related]
40. Metallothionein-III increases ADAM10 activity in association with furin, PC7, and PKCα during non-amyloidogenic processing.
Park BH; Kim HG; Jin SW; Song SG; Jeong HG
FEBS Lett; 2014 Jun; 588(14):2294-300. PubMed ID: 24859040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
